R_{10} is selected from hydrogen, OR_b, $OCOR_a$, $OCOOR_a$, and =O, with the proviso that when a =O group exists the hydrogen of the C atom to which the =O is attached is absent;

R_{13} is selected from hydrogen, COR_a, substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, and substituted or unsubstituted C_2-C_{12} alkynyl;

each R_a is independently selected from hydrogen, substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, substituted or unsubstituted C_2-C_{12} alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group;

each R_b is independently selected from hydrogen, substituted or unsubstituted C_1-C_{12} alkyl, substituted or unsubstituted C_2-C_{12} alkenyl, substituted or unsubstituted C_2-C_{12} alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, and substituted or unsubstituted sugar; and

the ------- line represents an additional bond, an epoxy group, or is absent;

or a pharmaceutically acceptable salt, ~~prodrug~~ or stereoisomer thereof.


2. A compound according to claim 1, wherein R_3, R_5, R_6, R_{14}, and R_{15} are each independently selected from hydrogen, OR_a, and $OCOR_a$, and wherein R_a is selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl.

3. A compound according to claim 2, wherein R_3, R_5, R_6, R_{14}, and R_{15} are hydrogen.

4. A compound according to any preceding claim, wherein R_{17} is a substituted or unsubstituted C_1-C_6 alkyl.

5. A compound according to claim 4, wherein R_{17} is methyl.

6. A compound according to claim 1, having the following formula **II**




(II)


wherein R_1, R_2, R_4, R_7, R_8-R_{13}, R_{16}, and the ------- line are as defined in claim 1, or a pharmaceutically acceptable salt, ~~prodrug~~ or stereoisomer thereof.

7. A compound according to any preceding claim, wherein R_1 and R_2 are each independently selected from hydrogen, halogen, OR_a, and $OCOR_a$, and wherein R_a is selected from hydrogen and substituted or unsubstituted C_1-C_6 alkyl.


8. A compound according to claim 7, wherein R_1 and R_2 are each independently selected from hydrogen and halogen.




Aegomycin E,



Aegomycin F,



Aegomycin G, or



Aegomycin H;

or a pharmaceutically acceptable salt, ~~prodrug~~ or stereoisomer thereof.

26. A pharmaceutical composition comprising a compound according to any preceding claim, or a pharmaceutically acceptable salt, ~~prodrug~~ or stereoisomer thereof, and a pharmaceutically acceptable carrier or diluent.

27. A compound according to any of claims 1 to 25, or a pharmaceutically acceptable salt, ~~prodrug~~ or stereoisomer thereof, for use as a medicament.

28. A compound according to 27 for use in the treatment of cancer.

29. Use of a compound according to any of claims 1 to 25, or a pharmaceutically acceptable salt, ~~prodrug~~ or stereoisomer thereof, in the preparation of a medicament for the treatment of cancer.